Dendritic Cell/AML Fusion vaccine (Dana-Farber Cancer Institute)

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameDendritic Cell/AML Fusion vaccine (Dana-Farber Cancer Institute)
Drug Alias NameDC/AML Fusion Vaccine (Dana-Farber Cancer Institute)
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCelgene CorpDana-Farber Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteCelgene Corp
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A